David Dai
Stock Analyst at SMBC Nikko
(0.16)
# 2,940
Out of 4,479 analysts
5
Total ratings
33.33%
Success rate
-39.09%
Average return
Main Sectors:
Top Industries:
5 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACET Adicet Bio | Initiates: Outperform | $28 | $1.10 | +2,445.45% | 1 | Mar 31, 2022 | |
| INBX Inhibrx | Initiates: Outperform | $40 | $13.56 | +194.99% | 1 | Mar 16, 2022 | |
| MGNX MacroGenics | Initiates: Outperform | $40 | $4.10 | +875.61% | 1 | Feb 4, 2022 | |
| NKTX Nkarta | Initiates: Outperform | n/a | $5.26 | - | 1 | Nov 18, 2021 | |
| JD JD.com | Upgrades: Outperform | n/a | $26.09 | - | 1 | Mar 17, 2020 |
Adicet Bio
Mar 31, 2022
Initiates: Outperform
Price Target: $28
Current: $1.10
Upside: +2,445.45%
Inhibrx
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $13.56
Upside: +194.99%
MacroGenics
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $4.10
Upside: +875.61%
Nkarta
Nov 18, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.26
Upside: -
JD.com
Mar 17, 2020
Upgrades: Outperform
Price Target: n/a
Current: $26.09
Upside: -